Motilal Oswal Alternates has raised over Rs 1,750 crore for its sixth real estate fund to invest in top eight cities of India ...

Motilal Oswal lists Sun Pharma, Mankind Pharma, Max Healthcare,, and Ipca Labs as its top picks in the sector.

Despite selective order inflow improvement, the strong existing order books provide healthy revenue visibility for companies ...

Brokerage firm Motilal Oswal has recommended three stocks - Mahindra and Mahindra, Kalyan Jewellers and Policy Bazaar - to ...

The Motilal Oswal Nifty Capital Market Index Fund Direct Growth has an AUM of - crores & has delivered CAGR of 0.00% in the last 5 years. The fund has an exit load of 1.00% and an expense ratio of ...

Pharma companies in India are expected to report healthy earnings growth in the just-concluded October-December quarter, ...

Index mutual funds are mutual fund schemes that track the performances of specific market indices. Index mutual funds, ...

The company's revenue is likely to grow by 6.3 per cent Y-o-Y on an average to Rs 6,445.63 crore as compared to Rs 6,060 ...

According to analysts, key metrics such as the total contract value (TCV) of deal wins, hiring trends, offshoring ratios, and ...

The government may fall short of its capital expenditure capex target for the financial year 2025 according to a report by Motilal Oswal ...

The Indian government's capital expenditure for FY25 is likely to fall short, as highlighted by a Motilal Oswal report. Despite a budget of Rs 11.1 trillion, only 39.1% has been spent in the first ...

Infosys Q3FY25 results forecast: analysts predict guidance revision, revenue growth, EBIT margin, deal wins, and headcount ...